Maa: Irlanti
Kieli: englanti
Lähde: HPRA (Health Products Regulatory Authority)
LEUPRORELIN ACETATE
Clear Pharma Limited
L02AE02
LEUPRORELIN ACETATE
Unknown
Product subject to prescription which may not be renewed (A)
Gonadotropin releasing hormone analogues
Authorised
2014-10-03
PACKAGE LEAFLET: INFORMATION FOR THE USER PROSTAP® 3 DCS 11.25 MG POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE Leuprorelin acetate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What PROSTAP 3 is and what it is used for 2. What you need to know before you take PROSTAP 3 3. How to take PROSTAP 3 4. Possible side effects 5. How to store PROSTAP 3 6. Contents of the pack and other information 1. WHAT PROSTAP 3 IS AND WHAT IT IS USED FOR PROSTAP 3 is a synthetic hormone which can be used to reduce the levels of testosterone and estrogen circulating in the body. PROSTAP 3 is used to treat prostate cancer in men and endometriosis and uterine fibroids in women. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PROSTAP 3 PROSTAP 3 IS NOT RECOMMENDED FOR USE IN CHILDREN UNDER THE AGE OF 18 YEARS. DO NOT TAKE PROSTAP 3: If you are allergic (hypersensitive) to leuprorelin acetate (PROSTAP SR, PROSTAP 3 or PROSTAP 6) or any of the other ingredients of PROSTAP 3 (listed in section 6). If you are a man with prostate cancer, and have had injections of a synthetic hormone in the Lue koko asiakirja
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT PROSTAP 3 DCS 11.25 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Powder: contains 11.25 mg leuprorelin acetate. Solvent: Solvent contains approximately 0.4mg (<1mmol) sodium (as carmellose sodium). When reconstituted with sterile solvent, the suspension contains 11.25mg of leuprorelin acetate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder and solvent for prolonged-release suspension for injection in pre-filled syringe (Dual Chamber Syringe). Powder: A sterile, lyophilised, white, odourless powder. Solvent: A clear odourless, slightly viscous, sterile solvent. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS (i) Management of prostatic carcinoma for which a suppression of testosterone is indicated. (ii) Management of estrogen dependent gynaecological disorders including the management of pain and lesions associated with endometriosis. (iii) Preoperative management of uterine fibroids to reduce their size and associated bleeding. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Male Adults: The usual recommended dose is 11.25mg presented as a 3 month depot injection and administered as a single subcutaneous or intramuscular injection at intervals of 3 months. The majority of patients will respond to this dosage. PROSTAP 3 therapy should not be discontinued when remission or improvement occurs. Response to PROSTAP 3 therapy may be monitored by clinical parameters and by measuring serum levels of testosterone and acid phosphatase. Clinical studies have shown that testosterone levels increased during the first 4 days of treatment in the majority of non-orchidectomised patients. They then decreased and reache Lue koko asiakirja